Improved assessment of axillary lymph node status with FAPI PET/CT led to restaging of nearly 71 percent of patients with breast cancer, according to new research presented at the SNMMI 2024 conference.
Can fibroblast activation protein inhibitor (FAPI) PET/CT have an impact in staging for women with newly diagnosed breast cancer?
For the study, which was presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, researchers compared clinical TNM staging between FAPI PET/CT and 18F-FDG PET/CT, which is commonly utilized in breast cancer staging. The cohort was comprised of 121 women with breast cancer. According to the study, 53 women had 68Ga-FAPI-04 PET/CT, 68 study participants had A118F-FAPI-04 PET/CT and all patients had 18F-FDG PET/CT scans.
The researchers found that FAPI PET/CT, in comparison to TNM staging with 18F-FDG PET/CT, restaged 19.8 percent of patients (24/121). Assessment of axillary lymph node (ALN) status by FAPI PET/CT was a significant factor for 17 of 24 patients (70.8 percent) who had TNM restaging, according to the study authors.
New research presented at the SNMMI 2024 conference found that FAPI PET/CT, in comparison to TNM staging with 18F-FDG PET/CT, restaged 19.8 percent of patients (24/121) with newly diagnosed breast cancer,
Noting the challenges with 18F-FDG PET/CT with respect to reduced sensitivity in certain breast cancer subtypes and false positives with inflammatory breast lesions, the researchers said the study findings show that FAPI PET/CT can be a viable alternative.
“This study is significant as it has the potential to advance personalized treatment strategies for breast cancer patients,” noted lead study author Zhixin Hao, M.D., a nuclear medicine physician affiliated with Peking Union Medical College Hospital in Beijing, China. “FAPI PET/CT for the initial staging of breast cancer has the potential to reduce unnecessary treatments and improve patient outcomes.”
The researchers also pointed out that FAPI PET/CT down-staged 20.6 percent of women (7/34) with initial IIB staging andupstaged 21.7 percent of patients (10/46) with initial IIA staging.
“Patients with stage IIA (breast cancer) should be considered for systemic staging with FAPI PET/CT at the time of initial diagnosis,” emphasized Hao and colleagues.
Reference
1. Hao Z, Pan B, Yao R, Zhou Y, Sun Q, Huo L. FAPI versus 18F-FDG PET/CT for systemic staging of newly diagnosed breast cancer. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 11, 2024.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.